FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM.
FUBIMINA acts as a reasonably potent agonist for the CB<sub>2</sub> receptor (K<sub>i</sub> = 23.45 nM), with 12x selectivity over CB<sub>1</sub> (K<sub>i</sub> = 296.1 nM), and does not fully substitute for ÃÂ<sup>9</sup>-THC in rat discrimination studies.
Related benzimidazole derivatives have been reported to be highly selective agonists for the CB<sub>2</sub> receptor.